ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
NEWS
2019
2020
2021
2022
No data
1
2
3
4
5
6
7
8
9
10
11
12
No data
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
27
27
28
29
30
31
No data
SEARCH
-BSI-082isafullyhumananti-SIRPαantagonisticmonoclonalantibodywithpotentialbroadcombotherapiesforthetreatmentofhematologicandsolidtumorsNEWARK,U.S.A.andNANJING,China—Jan24,2024,BiosionUSA,I...
2024-01-24
-FirstclinicaltrialtoevaluatethesafetyandefficacyofOBI-992(a.k.aBSI-992),anovelantibodydrugconjugate(ADC)targetingTROP2-DosingoffirstpatientinthePhase1/2clinicaltrialexpectedinearly2024NEWARK,U.S.A.an...
2024-01-08
NEWARK,U.S.A.andNANJING,China—Dec12,2023,CTTQPharma,partnerofBiosiontodayannouncedabstractshavebeenacceptedforposterpresentationatthe2023RevolutionizingAtopicDermatitis(RAD)VirtualConference.The...
2023-12-12
19
2023-09
Biosion Announces FDA Clearance of IND Application for BSI-082, a Novel Anti-SIRPα Monoclonal Antibody
19
2023-09
Biosion’s Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
19
2023-09
Biosion Partner CTTQ Pharma Published Phase I Study Data of IL-4Rα Antibody in 2023RAD Meeting
19
2023-09
Biosion Partner CTTQ Pharma Announces Phase II Trial of BSI-045B/TQC2731, a Novel anti-TSLP Antibody for Chronic Rhinosinusitis with Nasal Polyps, is Active and Recruiting Patients
19
2023-09
Biosion Announces Two Poster Presentations of Novel Antibody at SITC 2023
19
2023-09
Biosion Novel Antibody Therapies to be Featured at SITC 2023 (Society for Immunotherapy of Cancer)
上一页
1
2
3
4
5
下一页
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
NEWS
2019
2020
2021
2022
No data
1
2
3
4
5
6
7
8
9
10
11
12
No data
SEARCH
Biosion Announces FDA Clearance of IND Application for BSI-082, a Novel Anti-SIRPα Monoclonal Antibody
2024-01-24
Biosion’s Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
2024-01-08
Biosion Partner CTTQ Pharma Published Phase I Study Data of IL-4Rα Antibody in 2023RAD Meeting
2023-12-12
24
2024-01
Biosion Announces FDA Clearance of IND Application for BSI-082, a Novel Anti-SIRPα Monoclonal Antibody
08
2024-01
Biosion’s Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
12
2023-12
Biosion Partner CTTQ Pharma Published Phase I Study Data of IL-4Rα Antibody in 2023RAD Meeting
15
2023-11
Biosion Partner CTTQ Pharma Announces Phase II Trial of BSI-045B/TQC2731, a Novel anti-TSLP Antibody for Chronic Rhinosinusitis with Nasal Polyps, is Active and Recruiting Patients
05
2023-11
Biosion Announces Two Poster Presentations of Novel Antibody at SITC 2023
23
2023-10
Biosion Novel Antibody Therapies to be Featured at SITC 2023 (Society for Immunotherapy of Cancer)
上一页
1
2
3
4
5
下一页
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号